• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Ivenix Raises $50M to Pursue FDA Clearance of Next-Gen Infusion Pump System

by Jasmine Pennic 03/21/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Ivenix Smart Infusion Pump

Ivenix, a medical technology company developing the next-gen infusion system has raised $50 million in equity financing led by two new undisclosed investors, as well as participation from existing investors F-Prime Capital Partners and WuXi Healthcare Ventures, among others. The company plans to utilize the funding to pursue FDA clearance and quickly expand its team for commercial launch. Ivenix is focused on bringing its first solution to market, a new and innovative infusion system for hospitals.

What Are Infusion Pumps? 

Infusion pumps deliver a precise dose of medication, nutrients or fluid over an extended period of time when manual administration by nursing staff would not be practical, cost-effective or efficient. Many people are familiar with the most basic type of infusion as the simple saline drip

Large volume pumps are used throughout the hospital, from the general floors to critical care units and most areas in between.  Small volume pumps infuse fluids in more limited amounts, such as hormones and opiates.  Pumps are typically programmed to set the fluid flow rate and frequency, and liquids are dispensed from disposable bags.  The U.S. infusion pump market is projected to be $4.7B by 2017.  More than half of these are large volume pumps.

Smart Pumps

Smart pumps were introduced to help reduce medication errors by automating calculation of infusion dose and rates. They also include digital drug libraries enabling selection of medication from hospital-defined, customized lists.  To enhance safety, drugs may be subject to pre-programmed hard or soft dosing limits.  Smart pumps may also provide other safety features.  However, despite these efforts, serious pump errors continue.

The infusion pump industry is dominated by three large medical device manufacturers—CareFusion Corporation (recently acquired by Becton, Dickinson and Company), Baxter International and Hospira, Inc (recently acquired by ICU Medical).  Most manufacturers have not significantly upgraded their core designs for almost 20 years—well before today’s emphasis on healthcare IT—despite increasing complexity of drug dosing regimens, demand for EMR integration, and significant, widely reported patient safety issues. Any improvements have been incremental, as opposed to new, integrated solutions that focus on improving the fundamental underlying problems.

The Ivenix Infusion Management System addresses significant safety and performance gaps in existing pumps, while building in a broad, secure IT platform.  It includes a lightweight pump, IT platform proprietary administration set. 

 

– Ivenix’s fundamentally new pump technology significantly enhances safety and performance by measuring and adjusting infusion flow rate accurately in real time.  Infusions are delivered accurately and reliably regardless of such common variables as bag height, line pressure patient, movement and infusion viscosity and temperature under a wide range of clinical conditions and settings. The system also automates the complex, error-prone set-up of infusing multiple fluids and bags.

– A simple, intuitive smartphone-like user interface presents information in familiar ways and especially helps prevent programming and interpretation errors, empowering users to administer medications in less time and with fewer pump interactions. Studies show a large number of adverse infusion events are related to incorrect or incomplete programming. 

– Advanced wireless, web-based architecture enables anywhere, anytime access to patient infusion and pump management data from any computer or mobile device for more informed decision-making. It also provides infusion analytics and enables scalable integration with EMRs and other information systems for broad-based infusion information sharing and support of quality and cost capture initiatives. Advanced cyber security helps system integrity and information privacy.

“The demand for an innovative infusion system in healthcare is evident, and we are proud to support Ivenix as the trailblazer working to bring a truly revolutionary solution to this underserved market,” said Ketan Patel, MD, partner with F-Prime in a statement.  “Moreover, infusion pumps represent a $6 billion global market and offer significant opportunities for a high-performance infusion system that can meet the challenges of healthcare today, while providing the infrastructure to support the emerging technologies of tomorrow.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Infusion Pump, Ivenix

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |